Physician profile
Robert B Ballard
NPI 1902898182
$1,611.56
in general payments reported to CMS, 2019-2025
24 companies · $267 in 2025
The $267 reported for 2025 was less than what a typical Vascular Surgery provider received nationally (typical 2025 total: $927).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $278 · 2020: $43.48 · 2021: $130 · 2022: $425 · 2023: $199 · 2024: $269 · 2025: $267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $735.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $734.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $330.94 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $180.06 | 2021-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $170.83 | 2019-2022 | |
| Boston Scientific Corporation | $161.87 | 2023-2025 | Eluvia, Embold Fibered |
| Endologix LLC | $132.67 | 2019 | |
| Medtronic, INC. | $113.29 | 2021-2024 | Rapidcross |
| Inari Medical, INC. | $102.75 | 2024-2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Stryker Corporation | $66.89 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S, Artix Mt |
| Novartis Pharmaceuticals Corporation | $55.76 | 2025 | |
| Lemaitre Vascular, INC. | $33.59 | 2023 | Hydro Lemaitre Valvulotome, Restoreflow |
| Angiodynamics, INC. | $33.33 | 2021 | |
| Cook Medical LLC | $27.68 | 2023-2025 | Cook, Zenith Alpha |
| Becton, Dickinson and Company | $27.59 | 2024 | Rotarexs 6 F X 135 Cm |
| W. L. Gore & Associates, INC. | $26.23 | 2019 | |
| Surmodics, INC. | $22.92 | 2024 | Pounce Thrombectomy, Pounce Thrombectomy System, Pounce Venous Thrombectomy System |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $22.61 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $22.25 | 2025 | Lifevest |
| Phraxis, INC. | $21.78 | 2025 | |
| Medtronic Vascular, INC. | $15.06 | 2019 | |
| Pinnacle Biologics, INC | $14.38 | 2022 | |
| Davol INC. | $13.78 | 2019 | |
| Cardiva Medical, INC. | $12.88 | 2022 | |
| Cardiovascular Systems INC. | $2.42 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$23,347.27 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Ballard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.